← Back to Search

Radiopharmaceutical

Fluorine-18-L-dihydroxyphenylalanine for Malignant Glioma

Phase < 1
Waitlist Available
Led By Debra Brinkmann, PhD
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 10 years
Awards & highlights

Study Summary

This trial will compare the use of two types of scans to see which is better at identifying areas of the brain affected by tumors.

Eligible Conditions
  • Malignant Glioma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 10 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 10 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Treatment volume comparison
Secondary outcome measures
Advanced imaging volume comparison
Concordance with recurrence

Trial Design

1Treatment groups
Experimental Treatment
Group I: Fluorine-18-L-dihydroxyphenylalanineExperimental Treatment1 Intervention
18F-DOPA PET imaging will be used to guide radiotherapy treatment volumes and patients will be followed post-treatment to analyze response and patterns of failure

Find a Location

Who is running the clinical trial?

Brains Together for the CureUNKNOWN
Mayo ClinicLead Sponsor
3,212 Previous Clinical Trials
3,767,013 Total Patients Enrolled
Debra Brinkmann, PhDPrincipal InvestigatorMayo Clinic

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~2 spots leftby Apr 2025